SGLT1 Location and Expression
SGLT1 (sodium-glucose co-transporter 1) is primarily expressed in the small intestine and kidney, specifically in the late segments of the renal proximal tubules, and is also found throughout multiple regions of the central nervous system including the cerebellum, hippocampus, frontal cortex, and other brain areas 1.
Primary Expression Sites
Gastrointestinal System
- Small intestine (intestinal epithelium/enterocytes): This is the predominant site where SGLT1 mediates unidirectional absorption of glucose and galactose 1, 2
- SGLT1 plays a protective role in maintaining intestinal barrier integrity 2
Renal System
- Late segments of the proximal convoluted tubules: SGLT1 reabsorbs glucose that escapes upstream SGLT2-mediated reabsorption 3
- When SGLT2 is inhibited or overwhelmed, SGLT1-mediated glucose reabsorption increases 3
- Note: SGLT2 is predominantly expressed in the S1 and S2 segments of the proximal tubule and handles ~90% of filtered glucose reabsorption, while SGLT1 handles the remainder 1, 4
Central Nervous System
SGLT1 is extensively expressed in the brain 1:
- Cerebellum
- Hippocampus
- Frontal cortex
- Caudate nucleus
- Putamen
- Amygdala
- Parietal cortex
- Paraventricular nucleus of the hypothalamus
- Neuronal cell bodies and dendrites in multiple brain regions
The brain expression of SGLT1 is notably higher than SGLT2, though both co-exist in many CNS areas 1. SGLT1 in the brain plays a role in neuronal glucose transport and may be critical for neuronal survival during low glucose conditions or anoxia 1.
Other Tissues
- Pancreatic α-cells: SGLT1 is expressed in pancreatic α-cells and may be involved in glucagon secretion regulation 5, 6
- Cardiac tissue: SGLT1 is expressed in the human heart, with increased expression observed in hypertrophic, ischemic, and diabetic cardiomyopathy 7
- Various nonpolarized cells including some tumor cells 8
Clinical Relevance
The widespread distribution of SGLT1 explains why selective SGLT1 inhibition (like LX2761) acts primarily in the gastrointestinal tract to reduce glucose absorption without causing the glycosuria-related side effects seen with SGLT2 inhibitors 3. Dual SGLT1/2 inhibitors like sotagliflozin affect both intestinal glucose absorption and renal glucose reabsorption 1, 9.